Skip to content
Oligon Logo

Oligon to Present Three Abstracts at AACR 2022 Annual Meeting

SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Oligon™ Inc., an emerging biotechnology company developing a novel class of multimodal RNA therapeutics for the treatment of cancer and other diseases, announced today that three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022. The AACR 2022 Conference will be held in New Orleans, LA from April 8-13, 2022.
Dr. Spyro Mousses, CEO of Oligon, further commented, “Our SeekR™ RNA therapeutic platform is the best in class for single agent multitargeting, and we are thrilled at the opportunity to share our latest results with the cancer research community. Specifically, we will be publicly disclosing for the first time novel SeekR™ details and proprietary component compositions. Additionally, we will be presenting pre-clinical results for our lead cancer-targeting and IO-targeting candidates. In addition to our scientific presentations, our business development team and I will also be at the conference and available to meet with pharma partners who are interested in exploring strategic collaborations.”
Details of the abstracts are as follows:
Title: Development of novel anticancer RNA therapeutics with dual-targeting siRNA that silences ubiquitin family members
Abstract Number: 3977
Title: Development of multi-targeting immunomodulatory SeekR RNA therapeutics to overcome resistance to PD-1 blockade
Abstract Number: 4045
Title: Leveraging single-cell RNA sequencing data to design multi-targeting SeekR RNA therapeutics
Abstract Number: 5078
About Oligon
Oligon™ is developing a new class of multimodal RNA therapeutics that can simultaneously silence numerous disease targets with a single RNA molecule to improve outcomes and combat emerging drug resistance. Our proprietary SeekR™ platform is used to digitally engineer and rapidly produce self-delivering therapeutics which target specific tissues with unprecedented precision and accuracy. We are focused on building a pipeline of products in oncology, yet our multimodal RNA platform can be harnessed to transform outcomes for any complex multigenic disease.
To schedule a meeting during this conference, please contact: